Loading...
D. Western Therapeutics Institute, Inc.
4576.T•JPX
Healthcare
Biotechnology
¥114.00
¥0.00(0.00%)
D. Western Therapeutics Institute, Inc. (4576.T) Financial Performance & Income Statement Overview
Access detailed quarterly and annual financial reports for D. Western Therapeutics Institute, Inc. (4576.T), covering cash flow, earnings, and balance sheets.
Revenue Growth
10.09%
↑ 10.09%
Operating Income Growth
-51.47%
↓ 51.47%
Net Income Growth
-58.82%
↓ 58.82%
Operating Cash Flow Growth
-121.38%
↓ 121.38%
Operating Margin
-222.82%
↓ 222.82%
Gross Margin
84.48%
↑ 84.48%
Net Profit Margin
-241.55%
↓ 241.55%
ROE
-124.03%
↓ 124.03%
ROIC
-68.08%
↓ 68.08%
D. Western Therapeutics Institute, Inc. (4576.T) Income Statement & Financial Overview
Review D. Western Therapeutics Institute, Inc. 4576.T income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $122.67M | $125.39M | $118.70M | $104.82M |
| Cost of Revenue | $12.96M | $15.35M | $21.82M | $9.13M |
| Gross Profit | $109.71M | $110.04M | $96.89M | $95.69M |
| Gross Profit Ratio | $0.89 | $0.88 | $0.82 | $0.91 |
| R&D Expenses | $600.31M | $246.06M | $174.54M | $346.86M |
| SG&A Expenses | $71.41M | $61.72M | $53.40M | $68.00M |
| Operating Expenses | $671.66M | $307.84M | $227.94M | $414.49M |
| Total Costs & Expenses | $684.62M | $323.19M | $249.75M | $423.61M |
| Interest Income | $0.00 | $0.00 | $0.00 | $4000.00 |
| Interest Expense | $0.00 | $0.00 | $1.23M | $869000.00 |
| Depreciation & Amortization | $12.33M | $12.18M | $12.41M | -$790000.00 |
| EBITDA | -$549.68M | -$185.56M | -$185.80M | -$319.58M |
| EBITDA Ratio | -$4.48 | -$1.48 | -$1.57 | -$3.05 |
| Operating Income | -$561.95M | -$197.80M | -$131.05M | -$318.80M |
| Operating Income Ratio | -$4.58 | -$1.58 | -$1.10 | -$3.04 |
| Other Income/Expenses (Net) | -$759000.00 | -$8.30M | -$68.40M | -$1.66M |
| Income Before Tax | -$562.71M | -$206.10M | -$199.45M | -$320.45M |
| Income Before Tax Ratio | -$4.59 | -$1.64 | -$1.68 | -$3.06 |
| Income Tax Expense | $399000.00 | $399000.00 | $399000.00 | $398000.00 |
| Net Income | -$563.11M | -$206.50M | -$199.84M | -$320.85M |
| Net Income Ratio | -$4.59 | -$1.65 | -$1.68 | -$3.06 |
| EPS | -$14.24 | -$5.66 | -$6.18 | -$9.99 |
| Diluted EPS | -$14.24 | -$5.66 | -$6.18 | -$9.99 |
| Weighted Avg Shares Outstanding | $39.54M | $36.46M | $32.35M | $32.13M |
| Weighted Avg Shares Outstanding (Diluted) | $39.54M | $36.46M | $32.35M | $32.13M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan